APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cancer Immunotherapy Drug Market Analysis and Forecast 2026-2032

21 December 2025193 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drug Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Immunotherapy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cancer Immunotherapy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cancer Immunotherapy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cancer Immunotherapy Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Cancer Immunotherapy Drug include Novartis AG, Merck & Co., Inc., Jiangsu Hengrui Medicine Corporation, Pfizer, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Roche Holding AG, Medimmune, LLC and Juno Pharmaceuticals Pty Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Cancer Immunotherapy Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cancer Immunotherapy Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Cancer Immunotherapy Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Immunotherapy Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cancer Immunotherapy Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Cancer Immunotherapy Drug sales, projected growth trends, production technology, application and end-user industry.

Cancer Immunotherapy Drug Segment by Company

Novartis AG

Merck & Co., Inc.

Jiangsu Hengrui Medicine Corporation

Pfizer, Inc.

Bristol-Myers Squibb Company

AstraZeneca plc

Roche Holding AG

Medimmune, LLC

Juno Pharmaceuticals Pty Ltd.

Incyte Corporation

Gilead Sciences, Inc. (Kite Pharma)

Celgene Corporation

bluebird bio, Inc.

BeiGene

Autolus Therapeutics plc

Cancer Immunotherapy Drug Segment by Type

T-Cell Stimulant

PDL-1 Inhibitor

PD-1 Inhibitor

CTLA Antibody

Cancer Immunotherapy Drug Segment by Application

Hospital

Clinic

Others

Cancer Immunotherapy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Cancer Immunotherapy Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Immunotherapy Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Immunotherapy Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. T-Cell Stimulant Major Manufacturers Table 3. PDL-1 Inhibitor Major Manufacturers Table 4. PD-1 Inhibitor Major Manufacturers Table 5. CTLA Antibody Major Manufacturers Table 6. Global Cancer Immunotherapy Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Cancer Immunotherapy Drug Industry Trends Table 11. Cancer Immunotherapy Drug Industry Drivers Table 12. Cancer Immunotherapy Drug Industry Opportunities and Challenges Table 13. Cancer Immunotherapy Drug Industry Restraints Table 14. Global Cancer Immunotherapy Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Cancer Immunotherapy Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Cancer Immunotherapy Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2021-2026) Table 18. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2027-2032) Table 19. Global Cancer Immunotherapy Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Cancer Immunotherapy Drug Sales by Region (2021-2026) & (k units) Table 21. Global Cancer Immunotherapy Drug Sales by Region (2027-2032) & (k units) Table 22. Global Cancer Immunotherapy Drug Sales Market Share by Region (2021-2026) Table 23. Global Cancer Immunotherapy Drug Sales Market Share by Region (2027-2032) Table 24. Global Cancer Immunotherapy Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Cancer Immunotherapy Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Cancer Immunotherapy Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global Cancer Immunotherapy Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Cancer Immunotherapy Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Cancer Immunotherapy Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Cancer Immunotherapy Drug Manufacturers, Product Type & Application Table 32. Global Cancer Immunotherapy Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Cancer Immunotherapy Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Cancer Immunotherapy Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2026) Table 39. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2027-2032) Table 40. Global Cancer Immunotherapy Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 42. Global Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 43. Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2026) Table 44. Global Cancer Immunotherapy Drug Sales Market Share by Type (2027-2032) Table 45. Global Cancer Immunotherapy Drug Price by Type (2021-2026) & (US$/unit) Table 46. Global Cancer Immunotherapy Drug Price by Type (2027-2032) & (US$/unit) Table 47. Global Cancer Immunotherapy Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2026) Table 51. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2027-2032) Table 52. Global Cancer Immunotherapy Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 54. Global Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 55. Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2026) Table 56. Global Cancer Immunotherapy Drug Sales Market Share by Application (2027-2032) Table 57. Global Cancer Immunotherapy Drug Price by Application (2021-2026) & (US$/unit) Table 58. Global Cancer Immunotherapy Drug Price by Application (2027-2032) & (US$/unit) Table 59. Novartis AG Company Information Table 60. Novartis AG Business Overview Table 61. Novartis AG Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Novartis AG Cancer Immunotherapy Drug Product Portfolio Table 63. Novartis AG Recent Development Table 64. Merck & Co., Inc. Company Information Table 65. Merck & Co., Inc. Business Overview Table 66. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio Table 68. Merck & Co., Inc. Recent Development Table 69. Jiangsu Hengrui Medicine Corporation Company Information Table 70. Jiangsu Hengrui Medicine Corporation Business Overview Table 71. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio Table 73. Jiangsu Hengrui Medicine Corporation Recent Development Table 74. Pfizer, Inc. Company Information Table 75. Pfizer, Inc. Business Overview Table 76. Pfizer, Inc. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio Table 78. Pfizer, Inc. Recent Development Table 79. Bristol-Myers Squibb Company Company Information Table 80. Bristol-Myers Squibb Company Business Overview Table 81. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio Table 83. Bristol-Myers Squibb Company Recent Development Table 84. AstraZeneca plc Company Information Table 85. AstraZeneca plc Business Overview Table 86. AstraZeneca plc Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio Table 88. AstraZeneca plc Recent Development Table 89. Roche Holding AG Company Information Table 90. Roche Holding AG Business Overview Table 91. Roche Holding AG Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Roche Holding AG Cancer Immunotherapy Drug Product Portfolio Table 93. Roche Holding AG Recent Development Table 94. Medimmune, LLC Company Information Table 95. Medimmune, LLC Business Overview Table 96. Medimmune, LLC Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio Table 98. Medimmune, LLC Recent Development Table 99. Juno Pharmaceuticals Pty Ltd. Company Information Table 100. Juno Pharmaceuticals Pty Ltd. Business Overview Table 101. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio Table 103. Juno Pharmaceuticals Pty Ltd. Recent Development Table 104. Incyte Corporation Company Information Table 105. Incyte Corporation Business Overview Table 106. Incyte Corporation Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Incyte Corporation Cancer Immunotherapy Drug Product Portfolio Table 108. Incyte Corporation Recent Development Table 109. Gilead Sciences, Inc. (Kite Pharma) Company Information Table 110. Gilead Sciences, Inc. (Kite Pharma) Business Overview Table 111. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio Table 113. Gilead Sciences, Inc. (Kite Pharma) Recent Development Table 114. Celgene Corporation Company Information Table 115. Celgene Corporation Business Overview Table 116. Celgene Corporation Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Celgene Corporation Cancer Immunotherapy Drug Product Portfolio Table 118. Celgene Corporation Recent Development Table 119. bluebird bio, Inc. Company Information Table 120. bluebird bio, Inc. Business Overview Table 121. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio Table 123. bluebird bio, Inc. Recent Development Table 124. BeiGene Company Information Table 125. BeiGene Business Overview Table 126. BeiGene Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. BeiGene Cancer Immunotherapy Drug Product Portfolio Table 128. BeiGene Recent Development Table 129. Autolus Therapeutics plc Company Information Table 130. Autolus Therapeutics plc Business Overview Table 131. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio Table 133. Autolus Therapeutics plc Recent Development Table 134. North America Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (US$ Million) Table 135. North America Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (US$ Million) Table 136. North America Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 137. North America Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 138. North America Cancer Immunotherapy Drug Sales Price by Type (2021-2026) & (US$/unit) Table 139. North America Cancer Immunotherapy Drug Sales Price by Type (2027-2032) & (US$/unit) Table 140. North America Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 143. North America Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 144. North America Cancer Immunotherapy Drug Sales Price by Application (2021-2026) & (US$/unit) Table 145. North America Cancer Immunotherapy Drug Sales Price by Application (2027-2032) & (US$/unit) Table 146. North America Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. North America Cancer Immunotherapy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. North America Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 150. North America Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 151. North America Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 152. North America Cancer Immunotherapy Drug Sales Price by Country (2021-2026) & (US$/unit) Table 153. North America Cancer Immunotherapy Drug Sales Price by Country (2027-2032) & (US$/unit) Table 154. United States Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 155. Canada Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 156. Mexico Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 157. Europe Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 160. Europe Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 161. Europe Cancer Immunotherapy Drug Sales Price by Type (2021-2026) & (US$/unit) Table 162. Europe Cancer Immunotherapy Drug Sales Price by Type (2027-2032) & (US$/unit) Table 163. Europe Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (US$ Million) Table 164. Europe Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (US$ Million) Table 165. Europe Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 166. Europe Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 167. Europe Cancer Immunotherapy Drug Sales Price by Application (2021-2026) & (US$/unit) Table 168. Europe Cancer Immunotherapy Drug Sales Price by Application (2027-2032) & (US$/unit) Table 169. Europe Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Europe Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Europe Cancer Immunotherapy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Europe Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 173. Europe Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 174. Europe Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 175. Europe Cancer Immunotherapy Drug Sales Price by Country (2021-2026) & (US$/unit) Table 176. Europe Cancer Immunotherapy Drug Sales Price by Country (2027-2032) & (US$/unit) Table 177. Germany Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 178. France Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 179. U.K. Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 180. Italy Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 181. Russia Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 182. Spain Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 183. Netherlands Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 184. Switzerland Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 185. Sweden Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 186. Poland Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 187. China Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (US$ Million) Table 188. China Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (US$ Million) Table 189. China Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 190. China Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 191. China Cancer Immunotherapy Drug Sales Price by Type (2021-2026) & (US$/unit) Table 192. China Cancer Immunotherapy Drug Sales Price by Type (2027-2032) & (US$/unit) Table 193. China Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (US$ Million) Table 194. China Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (US$ Million) Table 195. China Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 196. China Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 197. China Cancer Immunotherapy Drug Sales Price by Application (2021-2026) & (US$/unit) Table 198. China Cancer Immunotherapy Drug Sales Price by Application (2027-2032) & (US$/unit) Table 199. Asia Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (US$ Million) Table 200. Asia Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (US$ Million) Table 201. Asia Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 202. Asia Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 203. Asia Cancer Immunotherapy Drug Sales Price by Type (2021-2026) & (US$/unit) Table 204. Asia Cancer Immunotherapy Drug Sales Price by Type (2027-2032) & (US$/unit) Table 205. Asia Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (US$ Million) Table 206. Asia Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (US$ Million) Table 207. Asia Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 208. Asia Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 209. Asia Cancer Immunotherapy Drug Sales Price by Application (2021-2026) & (US$/unit) Table 210. Asia Cancer Immunotherapy Drug Sales Price by Application (2027-2032) & (US$/unit) Table 211. Asia Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. Asia Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. Asia Cancer Immunotherapy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. Asia Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 215. Asia Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 216. Asia Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 217. Asia Cancer Immunotherapy Drug Sales Price by Country (2021-2026) & (US$/unit) Table 218. Asia Cancer Immunotherapy Drug Sales Price by Country (2027-2032) & (US$/unit) Table 219. Japan Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 220. South Korea Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 221. India Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 222. Australia Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 223. Taiwan Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 224. Southeast Asia Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 225. SAMEA Cancer Immunotherapy Drug Revenue by Type (2021-2026) & (US$ Million) Table 226. SAMEA Cancer Immunotherapy Drug Revenue by Type (2027-2032) & (US$ Million) Table 227. SAMEA Cancer Immunotherapy Drug Sales by Type (2021-2026) & (k units) Table 228. SAMEA Cancer Immunotherapy Drug Sales by Type (2027-2032) & (k units) Table 229. SAMEA Cancer Immunotherapy Drug Sales Price by Type (2021-2026) & (US$/unit) Table 230. SAMEA Cancer Immunotherapy Drug Sales Price by Type (2027-2032) & (US$/unit) Table 231. SAMEA Cancer Immunotherapy Drug Revenue by Application (2021-2026) & (US$ Million) Table 232. SAMEA Cancer Immunotherapy Drug Revenue by Application (2027-2032) & (US$ Million) Table 233. SAMEA Cancer Immunotherapy Drug Sales by Application (2021-2026) & (k units) Table 234. SAMEA Cancer Immunotherapy Drug Sales by Application (2027-2032) & (k units) Table 235. SAMEA Cancer Immunotherapy Drug Sales Price by Application (2021-2026) & (US$/unit) Table 236. SAMEA Cancer Immunotherapy Drug Sales Price by Application (2027-2032) & (US$/unit) Table 237. SAMEA Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 238. SAMEA Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 239. SAMEA Cancer Immunotherapy Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 240. SAMEA Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 241. SAMEA Cancer Immunotherapy Drug Sales by Country (2021-2026) & (k units) Table 242. SAMEA Cancer Immunotherapy Drug Sales by Country (2027-2032) & (k units) Table 243. SAMEA Cancer Immunotherapy Drug Sales Price by Country (2021-2026) & (US$/unit) Table 244. SAMEA Cancer Immunotherapy Drug Sales Price by Country (2027-2032) & (US$/unit) Table 245. Brazil Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 246. Argentina Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 247. Chile Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 248. Colombia Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 249. Peru Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 250. Saudi Arabia Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 251. Israel Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 252. UAE Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 253. Turkey Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 254. Iran Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 255. Egypt Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Table 256. Key Raw Materials Table 257. Raw Materials Key Suppliers Table 258. Cancer Immunotherapy Drug Distributors List Table 259. Cancer Immunotherapy Drug Customers List Table 260. Research Programs/Design for This Report Table 261. Authors List of This Report Table 262. Secondary Sources Table 263. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drug Image Figure 2. Global Cancer Immunotherapy Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. T-Cell Stimulant Image Figure 5. PDL-1 Inhibitor Image Figure 6. PD-1 Inhibitor Image Figure 7. CTLA Antibody Image Figure 8. Global Cancer Immunotherapy Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Cancer Immunotherapy Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Cancer Immunotherapy Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Cancer Immunotherapy Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global Cancer Immunotherapy Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Cancer Immunotherapy Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2021-2032) Figure 18. Global Cancer Immunotherapy Drug Sales (2021-2032) & (k units) Figure 19. Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Cancer Immunotherapy Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Cancer Immunotherapy Drug Sales YoY (2021-2032) & (k units) Figure 22. Europe Cancer Immunotherapy Drug Sales YoY (2021-2032) & (k units) Figure 23. China Cancer Immunotherapy Drug Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Cancer Immunotherapy Drug Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Cancer Immunotherapy Drug Sales YoY (2021-2032) & (k units) Figure 26. Global Cancer Immunotherapy Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Cancer Immunotherapy Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Cancer Immunotherapy Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Cancer Immunotherapy Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2032) Figure 32. Global Cancer Immunotherapy Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Cancer Immunotherapy Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2032) Figure 35. Global Cancer Immunotherapy Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Cancer Immunotherapy Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2032) Figure 38. Global Cancer Immunotherapy Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Cancer Immunotherapy Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2032) Figure 41. North America Cancer Immunotherapy Drug Revenue Share by Type (2021-2032) Figure 42. North America Cancer Immunotherapy Drug Sales Share by Type (2021-2032) Figure 43. North America Cancer Immunotherapy Drug Revenue Share by Application (2021-2032) Figure 44. North America Cancer Immunotherapy Drug Sales Share by Application (2021-2032) Figure 45. North America Cancer Immunotherapy Drug Revenue Share by Country (2021-2032) Figure 46. North America Cancer Immunotherapy Drug Sales Share by Country (2021-2032) Figure 47. Europe Cancer Immunotherapy Drug Revenue Share by Type (2021-2032) Figure 48. Europe Cancer Immunotherapy Drug Sales Share by Type (2021-2032) Figure 49. Europe Cancer Immunotherapy Drug Revenue Share by Application (2021-2032) Figure 50. Europe Cancer Immunotherapy Drug Sales Share by Application (2021-2032) Figure 51. Europe Cancer Immunotherapy Drug Revenue Share by Country (2021-2032) Figure 52. Europe Cancer Immunotherapy Drug Sales Share by Country (2021-2032) Figure 53. China Cancer Immunotherapy Drug Revenue Share by Type (2021-2032) Figure 54. China Cancer Immunotherapy Drug Sales Share by Type (2021-2032) Figure 55. China Cancer Immunotherapy Drug Revenue Share by Application (2021-2032) Figure 56. China Cancer Immunotherapy Drug Sales Share by Application (2021-2032) Figure 57. Asia Cancer Immunotherapy Drug Revenue Share by Type (2021-2032) Figure 58. Asia Cancer Immunotherapy Drug Sales Share by Type (2021-2032) Figure 59. Asia Cancer Immunotherapy Drug Revenue Share by Application (2021-2032) Figure 60. Asia Cancer Immunotherapy Drug Sales Share by Application (2021-2032) Figure 61. Asia Cancer Immunotherapy Drug Revenue Share by Country (2021-2032) Figure 62. Asia Cancer Immunotherapy Drug Sales Share by Country (2021-2032) Figure 63. SAMEA Cancer Immunotherapy Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA Cancer Immunotherapy Drug Sales Share by Type (2021-2032) Figure 65. SAMEA Cancer Immunotherapy Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA Cancer Immunotherapy Drug Sales Share by Application (2021-2032) Figure 67. SAMEA Cancer Immunotherapy Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA Cancer Immunotherapy Drug Sales Share by Country (2021-2032) Figure 69. Cancer Immunotherapy Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Cancer Immunotherapy Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • T-Cell Stimulant
  • PDL-1 Inhibitor
  • PD-1 Inhibitor
  • CTLA Antibody
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co., Inc.
  • Jiangsu Hengrui Medicine Corporation
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Roche Holding AG
  • Medimmune, LLC
  • Juno Pharmaceuticals Pty Ltd.
  • Incyte Corporation
  • Gilead Sciences, Inc. (Kite Pharma)
  • Celgene Corporation
  • bluebird bio, Inc.
  • BeiGene
  • Autolus Therapeutics plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cancer Immunotherapy Drug Market by Type
  3. 1.2.1 Global Cancer Immunotherapy Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 T-Cell Stimulant
  5. 1.2.3 PDL-1 Inhibitor
  6. 1.2.4 PD-1 Inhibitor
  7. 1.2.5 CTLA Antibody
  8. 1.3 Cancer Immunotherapy Drug Market by Application
  9. 1.3.1 Global Cancer Immunotherapy Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Cancer Immunotherapy Drug Market Dynamics
  1. 2.1 Cancer Immunotherapy Drug Industry Trends
  2. 2.2 Cancer Immunotherapy Drug Industry Drivers
  3. 2.3 Cancer Immunotherapy Drug Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Cancer Immunotherapy Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Cancer Immunotherapy Drug Revenue by Region
  3. 3.2.1 Global Cancer Immunotherapy Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cancer Immunotherapy Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Cancer Immunotherapy Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Cancer Immunotherapy Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Cancer Immunotherapy Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Cancer Immunotherapy Drug Sales by Region
  9. 3.4.1 Global Cancer Immunotherapy Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Cancer Immunotherapy Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Cancer Immunotherapy Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Cancer Immunotherapy Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Cancer Immunotherapy Drug Revenue by Manufacturers
  2. 4.1.1 Global Cancer Immunotherapy Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Cancer Immunotherapy Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Cancer Immunotherapy Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cancer Immunotherapy Drug Sales by Manufacturers
  6. 4.2.1 Global Cancer Immunotherapy Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Cancer Immunotherapy Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Cancer Immunotherapy Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Cancer Immunotherapy Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Cancer Immunotherapy Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Cancer Immunotherapy Drug Manufacturers, Product Type & Application
  13. 4.7 Global Cancer Immunotherapy Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Cancer Immunotherapy Drug Market CR5 and HHI
  16. 4.8.2 2025 Cancer Immunotherapy Drug Tier 1, Tier 2, and Tier 3
5 Cancer Immunotherapy Drug Market by Type
  1. 5.1 Global Cancer Immunotherapy Drug Revenue by Type
  2. 5.1.1 Global Cancer Immunotherapy Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Cancer Immunotherapy Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Cancer Immunotherapy Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Cancer Immunotherapy Drug Sales by Type
  6. 5.2.1 Global Cancer Immunotherapy Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Immunotherapy Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Cancer Immunotherapy Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Cancer Immunotherapy Drug Price by Type
6 Cancer Immunotherapy Drug Market by Application
  1. 6.1 Global Cancer Immunotherapy Drug Revenue by Application
  2. 6.1.1 Global Cancer Immunotherapy Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Cancer Immunotherapy Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Cancer Immunotherapy Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Cancer Immunotherapy Drug Sales by Application
  6. 6.2.1 Global Cancer Immunotherapy Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Cancer Immunotherapy Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Cancer Immunotherapy Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Cancer Immunotherapy Drug Price by Application
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Merck & Co., Inc.
  8. 7.2.1 Merck & Co., Inc. Company Information
  9. 7.2.2 Merck & Co., Inc. Business Overview
  10. 7.2.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
  12. 7.2.5 Merck & Co., Inc. Recent Developments
  13. 7.3 Jiangsu Hengrui Medicine Corporation
  14. 7.3.1 Jiangsu Hengrui Medicine Corporation Company Information
  15. 7.3.2 Jiangsu Hengrui Medicine Corporation Business Overview
  16. 7.3.3 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Jiangsu Hengrui Medicine Corporation Cancer Immunotherapy Drug Product Portfolio
  18. 7.3.5 Jiangsu Hengrui Medicine Corporation Recent Developments
  19. 7.4 Pfizer, Inc.
  20. 7.4.1 Pfizer, Inc. Company Information
  21. 7.4.2 Pfizer, Inc. Business Overview
  22. 7.4.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
  24. 7.4.5 Pfizer, Inc. Recent Developments
  25. 7.5 Bristol-Myers Squibb Company
  26. 7.5.1 Bristol-Myers Squibb Company Company Information
  27. 7.5.2 Bristol-Myers Squibb Company Business Overview
  28. 7.5.3 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bristol-Myers Squibb Company Cancer Immunotherapy Drug Product Portfolio
  30. 7.5.5 Bristol-Myers Squibb Company Recent Developments
  31. 7.6 AstraZeneca plc
  32. 7.6.1 AstraZeneca plc Company Information
  33. 7.6.2 AstraZeneca plc Business Overview
  34. 7.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
  36. 7.6.5 AstraZeneca plc Recent Developments
  37. 7.7 Roche Holding AG
  38. 7.7.1 Roche Holding AG Company Information
  39. 7.7.2 Roche Holding AG Business Overview
  40. 7.7.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
  42. 7.7.5 Roche Holding AG Recent Developments
  43. 7.8 Medimmune, LLC
  44. 7.8.1 Medimmune, LLC Company Information
  45. 7.8.2 Medimmune, LLC Business Overview
  46. 7.8.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
  48. 7.8.5 Medimmune, LLC Recent Developments
  49. 7.9 Juno Pharmaceuticals Pty Ltd.
  50. 7.9.1 Juno Pharmaceuticals Pty Ltd. Company Information
  51. 7.9.2 Juno Pharmaceuticals Pty Ltd. Business Overview
  52. 7.9.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
  54. 7.9.5 Juno Pharmaceuticals Pty Ltd. Recent Developments
  55. 7.10 Incyte Corporation
  56. 7.10.1 Incyte Corporation Company Information
  57. 7.10.2 Incyte Corporation Business Overview
  58. 7.10.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
  60. 7.10.5 Incyte Corporation Recent Developments
  61. 7.11 Gilead Sciences, Inc. (Kite Pharma)
  62. 7.11.1 Gilead Sciences, Inc. (Kite Pharma) Company Information
  63. 7.11.2 Gilead Sciences, Inc. (Kite Pharma) Business Overview
  64. 7.11.3 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Gilead Sciences, Inc. (Kite Pharma) Cancer Immunotherapy Drug Product Portfolio
  66. 7.11.5 Gilead Sciences, Inc. (Kite Pharma) Recent Developments
  67. 7.12 Celgene Corporation
  68. 7.12.1 Celgene Corporation Company Information
  69. 7.12.2 Celgene Corporation Business Overview
  70. 7.12.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
  72. 7.12.5 Celgene Corporation Recent Developments
  73. 7.13 bluebird bio, Inc.
  74. 7.13.1 bluebird bio, Inc. Company Information
  75. 7.13.2 bluebird bio, Inc. Business Overview
  76. 7.13.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
  78. 7.13.5 bluebird bio, Inc. Recent Developments
  79. 7.14 BeiGene
  80. 7.14.1 BeiGene Company Information
  81. 7.14.2 BeiGene Business Overview
  82. 7.14.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
  84. 7.14.5 BeiGene Recent Developments
  85. 7.15 Autolus Therapeutics plc
  86. 7.15.1 Autolus Therapeutics plc Company Information
  87. 7.15.2 Autolus Therapeutics plc Business Overview
  88. 7.15.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
  90. 7.15.5 Autolus Therapeutics plc Recent Developments
8 North America
  1. 8.1 North America Cancer Immunotherapy Drug Market Size by Type
  2. 8.1.1 North America Cancer Immunotherapy Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Cancer Immunotherapy Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Cancer Immunotherapy Drug Price by Type (2021-2032)
  5. 8.2 North America Cancer Immunotherapy Drug Market Size by Application
  6. 8.2.1 North America Cancer Immunotherapy Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Cancer Immunotherapy Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Cancer Immunotherapy Drug Price by Application (2021-2032)
  9. 8.3 North America Cancer Immunotherapy Drug Market Size by Country
  10. 8.3.1 North America Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Cancer Immunotherapy Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Cancer Immunotherapy Drug Market Size by Type
  2. 9.1.1 Europe Cancer Immunotherapy Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Cancer Immunotherapy Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Cancer Immunotherapy Drug Price by Type (2021-2032)
  5. 9.2 Europe Cancer Immunotherapy Drug Market Size by Application
  6. 9.2.1 Europe Cancer Immunotherapy Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Cancer Immunotherapy Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Cancer Immunotherapy Drug Price by Application (2021-2032)
  9. 9.3 Europe Cancer Immunotherapy Drug Market Size by Country
  10. 9.3.1 Europe Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Cancer Immunotherapy Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Cancer Immunotherapy Drug Market Size by Type
  2. 10.1.1 China Cancer Immunotherapy Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Cancer Immunotherapy Drug Sales by Type (2021-2032)
  4. 10.1.3 China Cancer Immunotherapy Drug Price by Type (2021-2032)
  5. 10.2 China Cancer Immunotherapy Drug Market Size by Application
  6. 10.2.1 China Cancer Immunotherapy Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Cancer Immunotherapy Drug Sales by Application (2021-2032)
  8. 10.2.3 China Cancer Immunotherapy Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cancer Immunotherapy Drug Market Size by Type
  2. 11.1.1 Asia Cancer Immunotherapy Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Cancer Immunotherapy Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Cancer Immunotherapy Drug Price by Type (2021-2032)
  5. 11.2 Asia Cancer Immunotherapy Drug Market Size by Application
  6. 11.2.1 Asia Cancer Immunotherapy Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Cancer Immunotherapy Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Cancer Immunotherapy Drug Price by Application (2021-2032)
  9. 11.3 Asia Cancer Immunotherapy Drug Market Size by Country
  10. 11.3.1 Asia Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Cancer Immunotherapy Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cancer Immunotherapy Drug Market Size by Type
  2. 12.1.1 SAMEA Cancer Immunotherapy Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Cancer Immunotherapy Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Cancer Immunotherapy Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Cancer Immunotherapy Drug Market Size by Application
  6. 12.2.1 SAMEA Cancer Immunotherapy Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Cancer Immunotherapy Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Cancer Immunotherapy Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Cancer Immunotherapy Drug Market Size by Country
  10. 12.3.1 SAMEA Cancer Immunotherapy Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Cancer Immunotherapy Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Cancer Immunotherapy Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Cancer Immunotherapy Drug Value Chain Analysis
  2. 13.1.1 Cancer Immunotherapy Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Cancer Immunotherapy Drug Production Mode & Process
  6. 13.2 Cancer Immunotherapy Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Cancer Immunotherapy Drug Distributors
  9. 13.2.3 Cancer Immunotherapy Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst